Treosulfan
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Oral, IV |
| ATC code | L01AB02 (WHO) |
| Identifiers | |
|
Systematic (IUPAC) name: (2S,3S)-2,3-Dihydroxybutane-1,4-diyl dimethanesulfonate
|
|
| Synonyms | 1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, Threitol 1,4-dimethanesulfonate, Threitol 1,4-bismethanesulfonate; L-Threitol 1,4-bis(methanesulfonate); Ovastat; Threosulphan; Treosulphan; Tresulfan |
| CAS Number | 299-75-2  |
| PubChem (CID) | 9296 |
| UNII | CO61ER3EPI  |
| Chemical and physical data | |
| Formula | C6H14O8S2 |
| Molar mass | 278.30056 g·mol−1 |
| Melting point | 101.5 to 105 °C (214.7 to 221.0 °F) |
| (what is this?) (verify) |
|
Treosulfan is a substance that is being studied in the treatment of cancer.[1] It belongs to the family of drugs called alkylating agents. It has been used mainly as a substitute of busulfan in frail patients, as the side effects and toxicity are supposedly less severe.
References[edit]
- ^ Schmittel A, Schmidt-Hieber M, Martus P, et al. (December 2006). "A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma". Ann. Oncol. 17 (12): 1826–9. doi:10.1093/annonc/mdl309. PMID 16971664.
External links[edit]
- Treosulfan entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
